Zentraler aortaler Blutdruck: Bedeutender Parameter für Diagnostik und Therapie

Abstract

In recent years great emphasis has been placed on the role of central aortic blood pressure as measured non invasively using pulse wave analysis in pathophysiology of cardiovascular diseases and clinical aspects of hypertension. The difference of blood pressure between the central aorta and the brachial artery (amplification) is not constant but varies according to physiological, pathological and pharmacological mechanisms. Central aortic blood pressure is more strongly related to cardiovascular organ damages than does brachial pressure. Several antihypertensive drugs have different effects on aortic blood pressure as compared with brachial pressure. Central aortic blood pressure emerges superior to brachial pressure as target blood pressure in antihypertensive treatment.

Die Messung des Blutdruckes ist wichtiger Bestandteil vieler Untersuchungen. Dabei gewinnt der zentrale aortale Blutdruck zunehmend an Interesse. Welche Verbindungen dieser Parameter zu hypertensiven Organschäden und verschiedenen Hypertonieformen hat und welche Rolle er bei der antihypertensiven Therapie spielt, wird in diesem Beitrag aufgezeigt.

Schlüsselwörter

Zentraler aortaler Blutdruck - Diagnostik - Hypertonie - Augmentation - antihypertensive Therapie

Key words

central aortic pressure - diagnosis - hypertension - augmentation - antihypertensive therapy

• Literatur

• 1 Frank O. Der Puls in den Arterien. Z Biol 1904; 46: 441-453
• 2 Middeke M. Otto Frank der Dynamiker. Dtsch Med Wochenschr 2012; 137: 2706-2711
• 3 Baulmann J, Nürnberger J, Slany J. et al. Arterielle Gefäßsteifigkeit und Pulswellenanalyse – Positionspapier zu Grundlagen, Methodik, Beeinflussbarkeit und Ergebnisinterpretation. Dtsch Med Wochenschr 2010; 1: 4-14
• 4 Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1281-1357
• 5 Roman MJ, Devereux RB, Kizer JR. et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure. Hypertension 2007; 50: 197-203
• 6 Herbert A, Cruickshank JK, Laurent S. et al. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J 2014; 35: 3122-3133
• 7 Kollias A, Lagou S, Zeniodi ME. et al. Association of Central Versus Brachial Blood Pressure With Target-Organ Damage: Systematic Review and Meta-Analysis. Hypertension 2016; 67 (01) 183-190
• 8 Protogerou AD, Argyris AA, Papaionannou TG. et al. Left ventricular hypertrophy is associated better with 24-h aortic pressure than 24-h brachial pressure in hypertensive patients: the SAFAR study. J Hypertens 2014; 32 (09) 1805-1814
• 9 Middeke M. Augmentation des aortalen Blutdruckes. Ursachen, kardiale Folgen und Konsequenzen für die antihypertensive Therapie. Akt Kardiol 2013; 2: 151-156
• 10 Lüers C, Trippel TD, Seeländer S. et al. Arterial stiffness and elevated left ventricular filling pressure in patients at risk for the development or a previous diagnosis of HF – A subgroup analysis from the DIAST-CHF study. J Am S Hyp 2017; 11 (05) 303-313
• 11 O´Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens 2013; 31: 649-654
• 12 Vlachopoulos C, Aznaouridis K, O’Rourke MF. et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865-1871
• 13 Williams B, Lacy PS, Thom SM. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225
• 14 Boutouyrie P, Achouba A, Trunet P. et al. Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination. Hypertension 2010; 55 (06) 1314-1322
• 15 Lindholm LH, Carlberg B, Samuelsson O. Should betablockers remain first choice in the treatment of primary hypertension? A Meta-analysis. Lancet 2005; 366: 1545-1553
• 16 Sarganas G, Knopf H, Grams D. et al. Trends in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension in Germany. Am J Hyp 2016; 29 (01) 104-113
• 17 Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21: 663-667
• 18 Dhakam Z, McEniery CM. Yasmin. et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26: 351-356 doi: 10.1097/HJH.0b013e3282f283c9
• 19 Kampus P, Serg M, Kals J. et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57: 1122-1128
• 20 Briasoulis A, Oliva R, Kalaitzidis R. et al. Effects of nebivolol on aortic compliance in patients with diabete and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich) 2013; 15: 473-479
• 21 Schattenkerk EDW, van den Bogaard B, Cammenga M. et al. Lack of difference between nebivolol/hydrochlorothiazide and metoprolol/hydrochlorothiazide on aortic wave augmentation and central blood pressure. J Hypertens 2013; 31: 2447-2454
• 22 Studinger P, Tabák KG, Chen CH. et al. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens (Greenwich) 2013; 15: 910-917
• 23 Redon J, Pascual-Izuel JM, Rodilla E. et al. Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study. Blood Press 2014; 23: 181-188